Abstract

Endoplasmic reticulum-associated degradation (ERAD) is a protein quality control mechanism that eliminates unwanted proteins from the endoplasmic reticulum (ER) through a ubiquitin-dependent proteasomal degradation pathway. gp78 is a previously described ER membrane-anchored ubiquitin ligase (E3) involved in ubiquitination of ER proteins. AAA ATPase (ATPase associated with various cellular activities) p97/valosin-containing protein (VCP) subsequently dislodges the ubiquitinated proteins from the ER and chaperones them to the cytosol, where they undergo proteasomal degradation. We now report that gp78 physically interacts with p97/VCP and enhances p97/VCP-polyubiquitin association. The enhanced association correlates with decreases in ER stress-induced accumulation of polyubiquitinated proteins. This effect is abolished when the p97/VCP-interacting domain of gp78 is removed. Further, using ERAD substrate CD3delta, gp78 consistently enhances p97/VCP-CD3delta binding and facilitates CD3delta degradation. Moreover, inhibition of endogenous gp78 expression by RNA interference markedly increases the levels of total polyubiquitinated proteins, including CD3delta, and abrogates VCP-CD3delta interactions. The gp78 mutant with deletion of its p97/VCP-interacting domain fails to increase CD3delta degradation and leads to accumulation of polyubiquitinated CD3delta, suggesting a failure in delivering ubiquitinated CD3delta for degradation. These data suggest that gp78-p97/VCP interaction may represent one way of coupling ubiquitination with retrotranslocation and degradation of ERAD substrates.

Highlights

  • Mammalian p97/VCP1 and its yeast counterpart CDC48 play crucial roles in a number of cellular processes in conjunction with its cofactors, Ufd1, Npl4, and p47 [1]

  • We demonstrated that gp78, a previously identified Endoplasmic reticulum-associated degradation (ERAD) E3 and the receptor for the tumor autocrine motility factor, interacts with p97/valosincontaining protein (VCP) and ubiquitin

  • By analyzing the ERAD substrate CD3␦, we demonstrated that gp78-p97/VCP interactions enhance p97/VCP-CD3␦ binding and facilitate CD3␦ degradation

Read more

Summary

Antibodies and Plasmids

Anti-green fluorescent protein (GFP) and anti-gp have been previously described [30]. Monoclonal antibody against p97/VCP was generated against a synthetic peptide derived from amino acids 792– 806 of the murine p97/ VCP (generously provided by Dr Chou-Chi Li), and some were purchased from Research Diagnostics. Gp fragment (amino acids 595– 643) was cloned into a pGEX4T3 vector for expressing glutathione S-transferase (GST) fusion gp78C49 protein. PCIneogp78⌬C49 was constructed by site-directed mutagenesis (QuikChange mutagenesis kit; Stratagene), whereby a stop codon was introduced to truncate the C-terminal 49 amino acids. PGEX4T2-gp78C⌬C65 and pGEX4T2-gp78C⌬C135 were generated by introducing stop codons in pGEX4T2-gp78C. The cDNA for hHrd (KIAA1810) in pBluescript was obtained from KAZUSA DNA Research Institute, Japan, and was subcloned into pCIneo vector using SalI and NotI sites. The resulting pCIneo-hHrd was tagged with FLAG through site-directed mutagenesis

Determination of Protein Interactions
RESULTS
Findings
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call